Resistance to abiraterone or enzalutamide is a major medical burden — the duration of benefit is highly variable and cross-resistance often occurs when these two agents are given sequentially. Blood-based analysis of androgen receptor splice variants and AR copy number gain or mutations could enhance understanding of the mechanisms of resistance and improve management of patients with castration-resistant prostate cancer.
References
Nakazawa, M., Antonarakis, E. S. & Luo, J. Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm. Cancer 5, 265–273 (2014).
Antonarakis E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028–1038 (2014).
Romanel, A. et al. Plasma AR and abiraterone-resistant prostate cancer. Sci. Transl Med. 7, 312re310 (2015).
Wyatt, A. W. et al. Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer. JAMA Oncol. http://dx.doi.org/10.1001/jamaoncol.2016.0494 (2016).
Scher, H. I. et al. Association of AR-V7 on circulating tumor cells as a tTeatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol., http://dx.doi.org/10.1001/jamaoncol.2016.1828 (2016).
Antonarakis, E. S. et al. Targeting the N-terminal domain of the androgen receptor: a new approach for the treatment of advanced prostate cancer. Oncologist http://dx.doi.org/10.1634/theoncologist.2016-0161 (2016).
Bernemann, C. et al. Expression of AR-V7 in circulating tumour cells does not preclude response to next generation androgen deprivation therapy in patients with castration resistant prostate cancer. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2016.07.021 (2016).
Antonarakis, E. et al. AR-V7 and efficacy of abiraterone (Abi) and enzalutamide (Enza) in castration-resistant prostate cancer (CRPC): expanded analysis of the Johns Hopkins cohort [abstract 5012]. J. Clin. Oncol. 34 (Suppl.) (2016).
Carreira, S. et al. Tumor clone dynamics in lethal prostate cancer. Sci. Transl Med. 6, 254ra125 (2014).
Miyamoto, D. T. et al. RNA-seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science 349, 1351–1356 (2015).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
G.A. has received honoraria, consulting fees or travel support from Astellas, Medivation, Janssen, Millennium Pharmaceuticals, Ipsen, Ventana, Bayer, Essa Pharma, Abbott Labs, Novartis, Veridex and Sanofi-Aventis, and grant support from Janssen, AstraZeneca, Innocrin and Arno. The Institute of Cancer Research (ICR) developed abiraterone and, therefore, has a commercial interest in this agent. G.A. is on the ICR list of rewards to inventors for abiraterone. E.S.A. has served as a paid consultant and/or adviser for Janssen, Astellas, Essa, and Medivation; has received research funding to his institution from Janssen, Johnson & Johnson, Medivation, and Tokai; and is a coinventor of a biomarker technology that has been licensed to Tokai.
Rights and permissions
About this article
Cite this article
Attard, G., Antonarakis, E. AR aberrations and resistance to abiraterone or enzalutamide. Nat Rev Urol 13, 697–698 (2016). https://doi.org/10.1038/nrurol.2016.212
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2016.212
- Springer Nature Limited
This article is cited by
-
Low TLR and PSMA-TV predict biochemical response to abiraterone acetate in metastatic prostate cancer patients developing castration resistance after chemohormonal therapy at hormone-sensitive stage
Journal of Cancer Research and Clinical Oncology (2023)
-
The androgen receptor/filamin A complex as a target in prostate cancer microenvironment
Cell Death & Disease (2021)
-
SEOM clinical guidelines for the treatment of advanced prostate cancer (2020)
Clinical and Translational Oncology (2021)
-
Bi-parametric magnetic resonance imaging based radiomics for the identification of benign and malignant prostate lesions: cross-vendor validation
Physical and Engineering Sciences in Medicine (2021)
-
Molecular mechanism of the TP53-MDM2-AR-AKT signalling network regulation by USP12
Oncogene (2018)